JOP20200232B1 - عملية لتحضير اثنين من مشتقات 4-{[(2s)-2-{4-[5-كلورو-2-(1h-1، 2، 3-تريازول-1-يل) فنيل]-5-مثوكسي-2-أوكسوبيريدين-1(2h)-يل} بيوتانويل] أمينو}-2-فلوروبنزاميد - Google Patents

عملية لتحضير اثنين من مشتقات 4-{[(2s)-2-{4-[5-كلورو-2-(1h-1، 2، 3-تريازول-1-يل) فنيل]-5-مثوكسي-2-أوكسوبيريدين-1(2h)-يل} بيوتانويل] أمينو}-2-فلوروبنزاميد

Info

Publication number
JOP20200232B1
JOP20200232B1 JOP/2020/0232A JOP20200232A JOP20200232B1 JO P20200232 B1 JOP20200232 B1 JO P20200232B1 JO P20200232 A JOP20200232 A JO P20200232A JO P20200232 B1 JOP20200232 B1 JO P20200232B1
Authority
JO
Jordan
Prior art keywords
chloro
amino
oxopyridin
butanoyl
triazol
Prior art date
Application number
JOP/2020/0232A
Other languages
English (en)
Inventor
Julian Egger 1
Daniel G?Tz 2
Michal Sowa 3
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of JOP20200232A1 publication Critical patent/JOP20200232A1/ar
Application granted granted Critical
Publication of JOP20200232B1 publication Critical patent/JOP20200232B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بعملية لتحضير 4-{[(2S)-2-{4-[5-كلورو-2-(4-كلورو-1H-1، 2، 3-تريازول-1-يل) فنيل]-5-مثوكسي-2-أوكسوبيريدين-1(2H)-يل} بيوتانويل] أمينو}-2-فلوروبنزاميد (I) أو 4-({(2S)-2-[4-{5-كلورو-2-[4-(ثلاثي فلورومثيل)-1H-1، 2، 3-تريازول-1-يل] فنيل}-5-مثوكسي-2-أوكسوبيريدين-1(2H)-يل] بيوتانويل} أمينو)-2-فلوروبنزاميد (II) من 2، 5-ثنائي مثوكسي بيريدين (III)، 1-(2-برومو-4-كلوروفنيل)-4-كلورو-1H-1، 2، 3-تريازول (X-Cl) أو 1-(2-برومو-4-كلوروفنيل)-4-(ثلاثي فلورومثيل)-1H-1، 2، 3-تريازول (X-CF3)، 4-أمينو-2-فلوروبنزاميد (XIII) وحمض (2R)-2-أمينو بيوتانويك (XVII)
JOP/2020/0232A 2018-03-15 2019-03-08 عملية لتحضير اثنين من مشتقات 4-{[(2s)-2-{4-[5-كلورو-2-(1h-1، 2، 3-تريازول-1-يل) فنيل]-5-مثوكسي-2-أوكسوبيريدين-1(2h)-يل} بيوتانويل] أمينو}-2-فلوروبنزاميد JOP20200232B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18161983 2018-03-15
PCT/EP2019/055815 WO2019175043A1 (en) 2018-03-15 2019-03-08 Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives

Publications (2)

Publication Number Publication Date
JOP20200232A1 JOP20200232A1 (ar) 2020-09-14
JOP20200232B1 true JOP20200232B1 (ar) 2023-09-17

Family

ID=61683650

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0232A JOP20200232B1 (ar) 2018-03-15 2019-03-08 عملية لتحضير اثنين من مشتقات 4-{[(2s)-2-{4-[5-كلورو-2-(1h-1، 2، 3-تريازول-1-يل) فنيل]-5-مثوكسي-2-أوكسوبيريدين-1(2h)-يل} بيوتانويل] أمينو}-2-فلوروبنزاميد

Country Status (28)

Country Link
US (1) US11542245B2 (ar)
EP (2) EP3889147A1 (ar)
JP (1) JP7287978B2 (ar)
KR (1) KR20200131241A (ar)
CN (1) CN111770917B (ar)
AR (1) AR117400A1 (ar)
AU (1) AU2019236369B2 (ar)
BR (1) BR112020018562A2 (ar)
CA (1) CA3093733A1 (ar)
CL (1) CL2020002371A1 (ar)
DK (1) DK3765452T3 (ar)
ES (1) ES2920449T3 (ar)
HR (1) HRP20220565T1 (ar)
HU (1) HUE058796T2 (ar)
IL (2) IL300463A (ar)
JO (1) JOP20200232B1 (ar)
LT (1) LT3765452T (ar)
MX (1) MX2020009580A (ar)
PE (1) PE20211395A1 (ar)
PL (1) PL3765452T3 (ar)
PT (1) PT3765452T (ar)
RS (1) RS63338B1 (ar)
SG (1) SG11202006710RA (ar)
SI (1) SI3765452T1 (ar)
TW (1) TWI823911B (ar)
UA (1) UA126940C2 (ar)
UY (1) UY38147A (ar)
WO (1) WO2019175043A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140558A (ko) * 2020-02-11 2022-10-18 케미노바 에이/에스 (r)-2-아미노부탄산으로부터 s-베플루부타미드를 합성하는 방법
EP4304714A1 (en) 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Crystalline forms of (4s)-2 4-chloro-4-ethyl-7 3-fluoro-3 5-methoxy-3 2,5-dioxo-1 4-(trifluoromethyl)-3 2h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-7 4-carboxamide
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CA3212644A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN107793396B (zh) 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
EP3898611A1 (en) * 2018-12-17 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
EP3898634A1 (en) * 2018-12-21 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
MA54521A (fr) * 2018-12-21 2022-03-30 Bayer Ag Dérivés d'oxopyridine substitués

Also Published As

Publication number Publication date
PE20211395A1 (es) 2021-07-27
CA3093733A1 (en) 2019-09-19
SI3765452T1 (sl) 2022-06-30
EP3765452A1 (en) 2021-01-20
ES2920449T3 (es) 2022-08-04
IL277240B1 (en) 2023-09-01
JOP20200232A1 (ar) 2020-09-14
TWI823911B (zh) 2023-12-01
PL3765452T3 (pl) 2022-08-01
KR20200131241A (ko) 2020-11-23
RU2020133706A (ru) 2022-04-18
HUE058796T2 (hu) 2022-09-28
JP2021517573A (ja) 2021-07-26
JP7287978B2 (ja) 2023-06-06
AU2019236369A1 (en) 2020-07-30
UY38147A (es) 2019-10-01
DK3765452T3 (da) 2022-06-27
EP3765452B1 (en) 2022-04-13
IL277240B2 (en) 2024-01-01
UA126940C2 (uk) 2023-02-22
US11542245B2 (en) 2023-01-03
HRP20220565T1 (hr) 2022-06-10
CN111770917B (zh) 2023-09-26
LT3765452T (lt) 2022-05-25
RS63338B1 (sr) 2022-07-29
EP3889147A1 (en) 2021-10-06
BR112020018562A2 (pt) 2020-12-29
AU2019236369B2 (en) 2024-04-18
WO2019175043A1 (en) 2019-09-19
IL300463A (en) 2023-04-01
US20210017152A1 (en) 2021-01-21
PT3765452T (pt) 2022-06-23
CN111770917A (zh) 2020-10-13
CL2020002371A1 (es) 2021-01-29
MX2020009580A (es) 2020-10-05
SG11202006710RA (en) 2020-08-28
AR117400A1 (es) 2021-08-04
IL277240A (en) 2020-10-29
TW202002969A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
JOP20200232B1 (ar) عملية لتحضير اثنين من مشتقات 4-{[(2s)-2-{4-[5-كلورو-2-(1h-1، 2، 3-تريازول-1-يل) فنيل]-5-مثوكسي-2-أوكسوبيريدين-1(2h)-يل} بيوتانويل] أمينو}-2-فلوروبنزاميد
AR017219A1 (es) Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
JP2014530194A5 (ar)
US6090807A (en) Use of heterocyclic compounds
TN2009000458A1 (en) Novel piperazine salts as d3/d2antagonists
EA023517B1 (ru) Модуляторы глюкагонового рецептора
JP2016526561A5 (ar)
JP2014529612A5 (ar)
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
KR970706259A (ko) 도파민 수용체 아류형 특이적 리간드로서 아미노메틸 페닐 이미다졸 유도체(certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands)
MX2010006260A (es) Composiciones orales de abt-263 para tratar cancer.
HUP0300158A2 (en) Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them
JOP20210227A1 (ar) شكل بلوري من مونوهيدرات 1-(1-أوكسو-1، 2-داي هيدروأيزوكينولين-5-يل)-5-(تراي فلوروميثيل)-n-(2-(تراي فلوروميثيل)بيريدين-4-يل)-1h-بيرازول-4-كربوكساميد
RU2017145929A (ru) МОДУЛЯТОРЫ ROR ГАММА(RORγ)
JP2009528319A5 (ar)
NZ701661A (en) Method for the preparation of triazole compounds
NO961333L (no) Nye pyrazolderivater som angiotensin-II-antagonister
RU2022129311A (ru) Способ получения двух 4-{ [(2s)-2-{ 4-[5-хлор-2-(1h-1,2,3-триазол-1-ил)фенил]-5-метокси-2-оксопиридин-1(2h)-ил} бутаноил]амино} -2-фторбензамидных производных
MX2023002979A (es) Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos.
JP2004525904A5 (ar)
SG11202107438WA (en) Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
MX370524B (es) Derivado de azol-benceno y forma cristalina del mismo.
IL307590A (en) 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1 -(((S)-OXETAN-2-YL)MTHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY
IL299657A (en) Pharmaceutical preparations including (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)M ETHYL) BENZYL)PIPERAZIN-1 -YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THEM